Trials / Unknown
UnknownNCT05470413
Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
A Randomized, Double-Blinded, and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (actual)
- Sponsor
- Reistone Biopharma Company Limited · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-central, double-blind, randomized, parallel, placebo-controlled phase 3 study in adult subjects with severe alopecia areata (SALT≥50%). Approximately 330 adult patients will be enrolled into the study. Efficacy and safety of two doses of SHR0302 will be compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR0302 | SHR0302 4 mg |
| DRUG | SHR0302 | SHR0302 8 mg |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2022-04-18
- Primary completion
- 2023-10-31
- Completion
- 2024-02-15
- First posted
- 2022-07-22
- Last updated
- 2023-09-05
Locations
31 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05470413. Inclusion in this directory is not an endorsement.